Auro Laboratories [AUROLAB] vs Sun Pharmaceutical [SUNPHARMA] Detailed Stock Comparison

Auro Laboratories Limited

BSE
Loading...

Sun Pharmaceutical Industries Ltd.

NSE
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Auro Laboratories Limited wins in 8 metrics, Sun Pharmaceutical Industries Ltd. wins in 11 metrics, with 0 ties. Sun Pharmaceutical Industries Ltd. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Auro Laboratories Limited Sun Pharmaceutical Industries Ltd. Better
P/E Ratio (TTM) 48.08 36.73 Sun Pharmaceutical Industries Ltd.
Price-to-Book Ratio 3.57 5.15 Auro Laboratories Limited
Debt-to-Equity Ratio 100.84 6.68 Sun Pharmaceutical Industries Ltd.
PEG Ratio 0.01 3.59 Auro Laboratories Limited
EV/EBITDA 31.14 23.61 Sun Pharmaceutical Industries Ltd.
Profit Margin (TTM) 11.39% 19.21% Sun Pharmaceutical Industries Ltd.
Operating Margin (TTM) 32.83% 26.17% Auro Laboratories Limited
EBITDA Margin (TTM) 32.83% 26.17% Auro Laboratories Limited
Return on Equity 4.28% 15.08% Sun Pharmaceutical Industries Ltd.
Return on Assets (TTM) 1.86% 11.87% Sun Pharmaceutical Industries Ltd.
Free Cash Flow (TTM) $-180.54M $119.44B Sun Pharmaceutical Industries Ltd.
Dividend Yield N/A 0.97% N/A
1-Year Return 11.96% 7.25% Auro Laboratories Limited
Price-to-Sales Ratio (TTM) 5.48 7.05 Auro Laboratories Limited
Enterprise Value $2.03B $3,783.37B Sun Pharmaceutical Industries Ltd.
EV/Revenue Ratio 7.13 6.66 Sun Pharmaceutical Industries Ltd.
Gross Profit Margin (TTM) 88.05% 80.96% Auro Laboratories Limited
Revenue per Share (TTM) $46 $237 Sun Pharmaceutical Industries Ltd.
Earnings per Share (Diluted) $5.20 $45.46 Sun Pharmaceutical Industries Ltd.
Beta (Stock Volatility) 0.09 0.11 Auro Laboratories Limited

Auro Laboratories Limited vs Sun Pharmaceutical Industries Ltd. Stock Performance Analysis

Loading Price Chart...

AUROLAB
SUNPHARMA

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Auro Laboratories Limited-1.52%-3.45%6.14%-8.81%2.74%7.86%
Sun Pharmaceutical Industries Ltd.-0.08%-3.03%-1.92%2.17%-1.01%3.92%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Auro Laboratories Limited11.96%219.81%161.67%1,083.37%3,551.32%4,900.00%
Sun Pharmaceutical Industries Ltd.7.25%79.99%166.96%144.01%669.48%2,278.32%

Performance & Financial Health Analysis: Auro Laboratories Limited vs Sun Pharmaceutical Industries Ltd.

MetricAUROLABSUNPHARMA
Market Information
Market Cap i₹1.56B₹3.88T
Market Cap CategorySmall capLarge cap
10 Day Avg. Volume i4,5573,903,142
90 Day Avg. Volume i4,5433,253,866
Last Close₹262.90₹1,788.50
52 Week Range₹159.00 - ₹317.00₹1,548.00 - ₹1,916.60
% from 52W High-17.07%-6.68%
All-Time High₹317.00 (Feb 18, 2026)₹1,960.35 (Sep 30, 2024)
% from All-Time High-17.07%-8.77%
Growth Metrics
Quarterly Revenue Growth2.08%0.14%
Quarterly Earnings Growth37.27%0.16%
Financial Health
Profit Margin (TTM) i0.11%0.19%
Operating Margin (TTM) i0.33%0.26%
Return on Equity (TTM) i0.04%0.15%
Debt to Equity (MRQ) i100.846.68
Cash & Liquidity
Book Value per Share (MRQ)₹70.01₹324.46
Cash per Share (MRQ)₹1.07₹115.87
Operating Cash Flow (TTM) i₹74.16M₹110.84B
Levered Free Cash Flow (TTM) i₹18.39M₹109.29B
Dividends
Last 12-Month Dividend Yield iN/A0.97%
Last 12-Month Dividend iN/A₹16.50

Valuation & Enterprise Metrics Analysis: Auro Laboratories Limited vs Sun Pharmaceutical Industries Ltd.

MetricAUROLAB (Apr 26, 2026)SUNPHARMA (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i48.0836.73
Forward P/E iN/A29.48
PEG Ratio i0.013.59
Price to Sales (TTM) i5.487.05
Price to Book (MRQ) i3.575.15
Market Capitalization
Market Capitalization i₹1.56B₹3.88T
Enterprise Value i₹2.03B₹3.78T
Enterprise Value Metrics
Enterprise to Revenue i7.136.66
Enterprise to EBITDA i31.1423.61
Risk & Other Metrics
Beta i0.090.11
Book Value per Share (MRQ) i₹70.01₹324.46

Financial Statements Comparison: Auro Laboratories Limited vs Sun Pharmaceutical Industries Ltd.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricAUROLAB (2025)SUNPHARMA (2025)
Revenue/Sales i191.24M520.41B
Cost of Goods Sold i99.08M121.98B
COGS % of Revenue i51.8%23.4%
Gross Profit i92.16M398.44B
Gross Margin i48.2%76.6%
Research & Development iN/AN/A
Operating Income (EBIT) i23.07M125.81B
Operating Margin i12.1%24.2%
EBITDA i40.60M167.25B
EBITDA Margin i21.2%32.1%
Pre-Tax Income i18.81M137.52B
Pre-Tax Income % of Revenue i9.8%26.4%
Income Tax i421,00027.72B
Income Tax % of Revenue i0.2%5.3%
Net Income (Profit) i18.39M109.65B
Profit Margin i9.6%21.1%

Balance Sheet & Liquidity Metrics

MetricAUROLAB (2025)SUNPHARMA (2025)
Cash & Equivalents i3,000102.69B
Total Current Assets i215.14M526.24B
Total Current Assets % of Revenue i112.5%101.1%
Total Current Liabilities i216.42M181.94B
Total Current Liabilities % of Revenue i113.2%35.0%
Long-Term Debt i330.85M3.58B
Long-Term Debt % of Revenue i173.0%0.7%
Total Shareholders Equity i429.68M724.86B
Retained Earnings i359.52M578.62B
Retained Earnings % of Revenue i188.0%111.2%
Property, Plant & Equipment i16.55M100.36B

Cash Flow Statement Comparison

MetricAUROLAB (2025)SUNPHARMA (2025)
Operating Cash Flow i74.16M110.84B
Operating Cash Flow % of Revenue i38.8%21.3%
Capital Expenditures i20,000-20.68B
Free Cash Flow i-180.54M119.44B
FCF Margin i-94.4%23.0%
Debt Repayment i0-43.44B
Common Stock Repurchase iN/A-29.00B

Short Interest & Institutional Ownership Analysis

MetricAUROLABSUNPHARMA
Shares Short iN/AN/A
Short Ratio iN/AN/A
Short % of Float iN/AN/A
Shares Outstanding i6.23M2.40B
Float Shares i2.35M1.07B
% Held by Insiders i60.96%55.62%
% Held by Institutions i0.00%28.69%
% Held by Public i39.04%15.69%

Dividend Analysis & Yield Comparison: Auro Laboratories Limited vs Sun Pharmaceutical Industries Ltd.

MetricAUROLABSUNPHARMA
Last 12-Month Dividend iN/A₹16.50
Last 12-Month Dividend Yield iN/A0.97%
3-Year Avg Annual Dividend iN/A₹17.33
3-Year Avg Dividend Yield iN/A0.51%
3-Year Total Dividends iN/A₹52.00
Ex-Dividend DateN/AFeb 05, 2026